10 / 27
Page 52
Volume 09
Journal of Alzheimers Disease & Parkinsonism
ISSN: 2161-0460
Epilepsy 2019
Parkinsons Congress 2019
August 29-31, 2019
JOINT EVENT
conferenceseries
.com
August 29-31, 2019 Vienna, Austria
&
5
th
International Conference on
Epilepsy & Treatment
5
th
World Congress on
Parkinsons & Huntington Disease
Parkinson’s disease: Allogeneic cell replacement therapeutic approach with a novel neural cell line
Ashok Chakraborty and Anil Diwan
AllExcel, Inc., USA
Background:
Parkinson’s disease is caused by the progressive impairment or deterioration of neurons (nerve cells)
in an area of the brain known as Substantia Nigra.
Objective:
Curative therapy for Parkinson’s disease; Current therapies are based on dopamine supplementation in
the brain. They are only palliative, and require adjunct therapies to minimize side effects. Yet long term side effects
such as motor neuron defect and Bradykinesia, Dyskinesia etc occur; Cell Replacement Therapy is the only approach
that promises functional reversal of Parkinson’s disease.
Methods:
AllExcel, Inc. has developed a platform technology for developing designed, functionally improved cell
lines without the use of viral vectors or DNA manipulation. Technology is based on concepts derived from naturally
observed Human Cell-Cell Interactions (CCITM).
Results:
Fast growing potent Dopaminergic cell lines have been produced with long survival in cell culture. In animal
studies (6-OHDA treated Rat model for PD), four different clones showed very effective reversal of the disease.
Conclusion:
Highly potent modified neural cells have been produced in our lab to treat PD patients.
J Alzheimers Dis Parkinsonism 2019, Volume 09